



Editor's choice  
Scan to access more  
free content

## ORIGINAL ARTICLE

# Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease

Ali Balci,<sup>1,2</sup> Krystyna M Solлие-Szarynska,<sup>3</sup> Antoinette G L van der Bijl,<sup>2</sup> Titia P E Ruys,<sup>4</sup> Barbara J M Mulder,<sup>5</sup> Jolien W Roos-Hesselink,<sup>4</sup> Arie P J van Dijk,<sup>6</sup> Elly M C J Wajon,<sup>7</sup> Hubert W Vliegen,<sup>8</sup> Willem Drenthen,<sup>2</sup> Hans L Hillege,<sup>2,9</sup> Jan G Aarnoudse,<sup>4</sup> Dirk J van Veldhuisen,<sup>2</sup> Petronella G Pieper,<sup>2</sup> On behalf of the ZAHARA-II investigators

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/heartjnl-2014-305597>).

For numbered affiliations see end of article.

## Correspondence to

Dr. P.G. Pieper, Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen 9700 RB, The Netherlands  
E-mail: [p.g.pieper@umcg.nl](mailto:p.g.pieper@umcg.nl) or Dr Ali Balci, Department of Cardiology, Isala, PO Box 10.400, Zwolle, 8000 GK, The Netherlands  
[drbalci@gmail.com](mailto:drbalci@gmail.com)

Received 27 January 2014

Revised 20 May 2014

Accepted 5 June 2014

Published Online First

17 July 2014



► <http://dx.doi.org/10.1136/heartjnl-2014-306060>



CrossMark

**To cite:** Balci A, Solлие-Szarynska KM, van der Bijl AGL, et al. *Heart* 2014;**100**:1373–1381.

## ABSTRACT

**Objectives** Adequate prepregnancy prediction of maternal cardiovascular and offspring risk is important for counselling and management of pregnancy in women with congenital heart disease (CHD). Therefore we performed a study to identify the optimal assessment strategy for estimating the risk of pregnancy in women with CHD.

**Methods** In this prospective study, we determined the outcomes of 213 pregnancies in 203 women with CHD. The ZAHARA I (Zwangerschap bij Aangeboren HARTafwijkingen I) and CARPREG (CARdiac disease in PREGnancy) risk scores were calculated for each pregnancy, as was the total number of cardiovascular (TPC) or offspring risk predictors (TPo) from these and other studies combined. Pregnancies were also classified according to the modified WHO classification of maternal cardiovascular risk and according to disease complexity (DC).

**Results** Maternal cardiovascular events occurred during 22 pregnancies (10.3%). Offspring events occurred during 77 pregnancies in 81 children (37.3%). Cardiovascular and offspring event rates increased with higher risk scores, higher TPC or TPo, higher WHO class and greater DC. The highest area under the curve (AUC) for maternal cardiovascular risk was achieved by the WHO class (AUC: 0.77,  $p < 0.0001$ ). AUC for the ZAHARA I risk score was 0.71 ( $p = 0.001$ ), and for the CARPREG risk score 0.57 ( $p = 0.32$ ). All models performed insufficiently in predicting offspring events ( $AUC \leq 0.6$ ).

**Conclusions** The WHO classification is the best available risk assessment model for estimating cardiovascular risk in pregnant women with CHD. None of the offspring prediction models perform adequately in our cohort.

## INTRODUCTION

Pregnancy in women with structural congenital heart disease (CHD) is associated with increased maternal cardiac and offspring risk. Mothers with CHD are mainly at risk of developing arrhythmias and episodes of heart failure, whereas the offspring is mainly at risk of premature birth, small for gestational age and mortality.<sup>1–8</sup> The magnitude of

cardiac and offspring risk depends on the underlying CHD, and is attributable to the complexity of the heart disease and (residual) lesions such as valvular and ventricular dysfunction.<sup>1 2 7</sup> For the attending cardiologist, adequate risk assessment is essential to optimise prepregnancy counselling and pregnancy management.

Several classifications and risk scores are available to estimate the maternal cardiac and offspring risk associated with pregnancy in women with CHD.<sup>2 5 7 9 10</sup> Risk assessment models developed by the CARPREG (CARdiac disease in PREGnancy) investigators and by our own ZAHARA (Zwangerschap bij Aangeboren HARTafwijkingen, pregnancy in CHD) research group provide quantification of maternal cardiovascular and offspring risk of pregnancy.<sup>2 7</sup> Both identified independent predictors of maternal cardiovascular and offspring events, as described elsewhere in detail.<sup>2 7</sup> Both models attribute points to each predictor of maternal cardiovascular risk, thus attributing a certain cardiovascular and offspring risk to the pregnancy. Additional predictors were identified by Khairy *et al*.<sup>5</sup> The European Society of Cardiology guidelines for the management of heart disease in pregnancy advise to estimate maternal risk according to the modified WHO classification.<sup>9 11</sup> This classification integrates knowledge from the total body of literature and takes into account the underlying heart disease, ventricular and valvular function, as well as predictors identified by several studies. Patients are classified as low, moderate or high risk, or contraindication for pregnancy.<sup>9 11</sup> Because risk of pregnancy is associated with disease complexity (DC), risk assessment may also be performed using a generally accepted DC classification.<sup>1 10 12</sup> A prospective external validation and comparison of the abovementioned risk scores and risk assessment models has not been performed.

We therefore aimed in this prospective multicenter study to provide external validation of the CARPREG and ZAHARA I risk scores, and to compare the different risk assessment models in order to identify the optimal assessment strategy for estimating the risk of cardiovascular and offspring events of pregnancy in women with CHD.

## PATIENTS AND METHODS

### Design and setting

This prospective observational multicenter cohort study was conducted between March 2008 and August 2011. The extensive study design of the ZAHARA II study was published previously and is summarised below.<sup>13</sup>

### Patient selection

All consecutive pregnant women with structural CHD ( $\geq 18$  years) reporting pregnancy with a duration  $\leq 20$  weeks, who provided written informed consent, and who were followed in one of the eight participating hospitals, were eligible for enrolment. Miscarriages or termination before 20 weeks gestation were excluded, as were women with known illicit drug or alcohol abuse.

### Baseline characteristics

Medical records were used to collect baseline data at the first prenatal visit at 20 weeks gestation including: maternal age, smoking, alcohol consumption, medications, obstetric history, medical history, presence of cyanosis (oxygen saturation  $< 90\%$ ), underlying heart disease, prior interventions, cardiac sequelae, cardiovascular event history, New York Heart Association (NYHA) functional class before and during pregnancy as well as postpartum, prior and present cardiac status including ventricular and valvular function assessed according to the recommendations and guidelines of the European Association of Echocardiography/American Society of Echocardiography.<sup>14–17</sup>

### Risk assessment

Maternal cardiovascular and offspring risk of pregnancy were scored by two investigators who were ignorant of pregnancy outcome according to the aforementioned risk assessment models using the baseline characteristics. The final score was based on consensus. Based on the presence of independent predictors, the ZAHARA I and CARPREG maternal cardiovascular risk scores were calculated (table 1).<sup>2–7</sup> Although the previously published ZAHARA I and CARPREG studies presented independent predictors for offspring events, both papers lacked a risk score for offspring events. Since we had full access to the ZAHARA I data, we were able to calculate the ZAHARA I offspring risk score using identical methodology as previously described for the maternal cardiac risk score.<sup>2</sup> To calculate the ZAHARA I offspring risk score, we used the exponent value of the previously identified independent predictors for the composite offspring endpoint to weigh the risk factors and attribute points per risk factor (see online supplementary appendix 1 for details). Table 1 describes the ZAHARA I offspring risk score and the corresponding offspring risk during pregnancy. We also developed an offspring risk score based on the independent predictors identified in the CARPREG study by using the exponent value of the odds ratios (ORs) from the independent predictors for offspring events published by the CARPREG investigators to weigh the risk factors and attribute points per risk factor<sup>7</sup> (table 1). Additionally, the total number of (non-overlapping) predictors of maternal cardiovascular events and offspring events (TPo) of ZAHARA I and CARPREG, as well as the predictors from the study of Khairy *et al*, were assessed (predictors of the study of Khairy *et al* for maternal risk were: severe pulmonary regurgitation or subpulmonary ventricular dysfunction and smoking history; for offspring risk: subaortic ventricular outflow tract gradient  $> 30$  mm Hg). Patients were also classified according to the modified WHO classification of pregnancy risk

(table 1) and according to DC.<sup>9–11</sup> For DC, we used the generally accepted three categories of Warnes *et al*.<sup>10</sup> simple CHD (ie, isolated aortic or mitral valve disease, small atrial septal defect, mild pulmonic stenosis, repaired atrial or ventricular septal defect), moderate complex CHD (ie, atrioventricular septal defect, coarctation, Ebstein's anomaly, tetralogy of Fallot) and complex CHD (ie, cyanotic CHD, transposition of the great arteries, Fontan procedure, truncus arteriosus).

### Endpoints

We scored maternal cardiovascular and offspring events for each pregnancy according to the definitions used in the CARPREG and ZAHARA I studies.<sup>2–7</sup> Primary cardiovascular events were: cardiovascular mortality, clinically significant (needing treatment) arrhythmia, clinically significant (needing treatment) heart failure, thromboembolic events (eg, pulmonary embolism, valve thrombosis or deep venous thrombosis), vascular events (eg, stroke, myocardial infarction or dissection), need for urgent or invasive cardiovascular intervention up to 6 months postpartum, and endocarditis.<sup>2–7</sup> Secondary cardiac events were: NYHA class deterioration  $\geq 2$  points compared to baseline. Offspring events were: fetal death, neonatal death, premature birth (delivery  $< 37$  weeks gestation), small for gestational age birth weight ( $< 10$ th percentile), respiratory distress syndrome, infections leading to hospital admission, neonatal intensive care unit admission, cerebral intraventricular haemorrhage, occurrence of CHD and occurrence of other congenital disease.

### Statistical analysis

We used SPSS (IBM SPSS Statistics, V19.0, IBM SPSS Statistics, IBM Corporation, Armonk, New York, USA) and STATA (V12.0, StatCorp LP, College Station, Texas, USA) for statistical analysis. Descriptive statistics for nominal data were expressed in absolute numbers and percentages. Continuous variables with normal distribution are presented as mean with standard deviation (SD) ( $\pm$ SD), whereas non-normal distributed variables as median with inter quartile range (IQRs), and dichotomous variables are presented as absolute numbers with percentages. All p values are two-sided. External validation of the CARPREG cardiovascular risk score and ZAHARA I cardiovascular and offspring risk scores were performed by plotting the expected versus observed event rates. We also calculated the area under the receiver operating characteristic (ROC) curve (AUC) to compare the discriminative capacity of the different cardiovascular and offspring models.<sup>18–19</sup> An AUC  $> 0.90$  is generally considered perfect, while an AUC  $< 0.70$  is considered poor, and an AUC = 0.5 is considered a worthless test. The best combination of risk assessment models was assessed by calculating the AUC following logistic models for the different test combinations. The p value for the AUC was calculated using the  $\chi^2$ -test, testing for random guess (AUC = 0.5). The calibration of the model was assessed using the Hosmer-Lemeshow Goodness-of-fit test.<sup>20</sup>

### Ethical considerations

The Dutch Heart Foundation had no role in the design, data collection, analysis, interpretation, writing of the manuscript or the decision to submit for publication of this manuscript. The corresponding author has full access to all data and the responsibility for the submission of this manuscript for publication.

### RESULTS

We Identified 234 women with structural CHD who were eligible for participation. Twenty-one women were excluded, because of miscarriage (n = 11), serious protocol violation (n = 6)

**Table 1** CARPREG and ZAHARA maternal cardiovascular and offspring risk scores, and modified WHO classification of maternal risk

Predictor	Risk points (maternal risk)	Risk points (offspring risk)
<b>CARPREG</b>		
Prior cardiac event (heart failure, transient ischaemic attack, stroke, arrhythmia)	1	–
NYHA functional class III/IV or cyanosis (SpO <sub>2</sub> <90%)	1	1
Left heart obstruction (mitral valve area <2 cm <sup>2</sup> or aortic valve area <1.5 cm <sup>2</sup> or peak LVOT gradient >30 mm Hg (echocardiography)	1	0.75
Reduced systemic ventricular systolic function (EF <40%)	1	–
Multiple gestation	–	3
Smoking	–	1
Heparin/warfarin during pregnancy	–	1
<b>ZAHARA</b>		
Prior arrhythmia	1.50	–
NYHA functional class III/IV	0.75	–
Left heart obstruction (peak LVOT gradient >50 mm Hg or aortic valve area <1.0 cm <sup>2</sup>	2.50	–
Mechanical valve prosthesis	4.25	2.50
Systemic atrioventricular valve regurgitation (moderate/severe)	0.75	–
Pulmonary atrioventricular valve regurgitation (moderate/severe)	0.75	–
Cardiac medication before pregnancy	1.50	0.75
Cyanotic heart disease (corrected and uncorrected)	1.00	0.75
Twin or multiple gestation	–	1.75
Smoking during pregnancy	–	0.50
<b>Modified WHO Classification</b>		
Conditions in which maternal risk is WHO class I		
Uncomplicated, small or mild pulmonary stenosis		
Successfully repaired simple lesions (atrial or ventricular septal defect, patent ductus arteriosus, anomalous pulmonary venous drainage)		
Conditions in which maternal risk is WHO class II or III		
WHO class II (if otherwise well and uncomplicated)		
Unoperated atrial or ventricular septal defect, repaired tetralogy of Fallot		
WHO class II–III (depending on individual)		
Native or tissue valvular heart disease not considered WHO I or IV; repaired coarctation; Marfan syndrome without aortic dilatation, bicuspid valve with aorta <45 mm; mild ventricular impairment		
WHO class III		
Mechanical valve; systemic RV; Fontan circulation; unrepaired cyanotic heart disease; other complex congenital heart disease; Marfan syndrome with aorta 40–45 mm; bicuspid aortic valve with aorta 45–50 mm		
Conditions in which pregnancy risk is WHO class IV (contra-indicated)		
Pulmonary hypertension/Eisenmenger syndrome; systemic ventricular EF <30% or systemic ventricular dysfunction with NYHA class III–IV; severe mitral stenosis, severe symptomatic aortic stenosis, Marfan syndrome with aorta >45 mm; bicuspid aortic valve with aorta >50 mm; native severe coarctation		

**CARPREG Risk Score:** For each CARPREG predictor that is present, a predictor-specific number of points is assigned for maternal cardiovascular risk or offspring risk, according to the table. The risk score (either maternal or offspring) is the total number of points. The risk of maternal cardiovascular complication is 5% with 0 points, 27% with 1 point and 75% with ≥1 point. The risk of offspring complications is higher with a higher risk score; no percentages are assigned to the score. **ZAHARA risk score:** for each ZAHARA predictor that is present, a predictor-specific number of points is assigned to the pregnancy, according to the table. The risk of maternal cardiovascular complications is 2.9% with <0.50 points, 7.5% with 0.51–1.50 points, 17.5% with 1.51–2.50 points, 43.1% with 2.51–3.50 points and 70% with >3.51 points. The risk of offspring complications is 19.9% with <0.50 risk points, 33.3% with 0.50–0.99 risk points, 46.7% with 1.0–1.49 risk points, and 59.6% with ≥1.50 risk points. **Modified WHO classification:** Class I: no detectable increased risk of maternal mortality and no/mild increase in morbidity; Class II: small increased risk of maternal mortality or moderate increase in morbidity; Class III: significantly increased risk of maternal mortality or severe morbidity; Class IV: extremely high risk of maternal mortality or severe morbidity, pregnancy is contra-indicated.

CARPREG, CARDiac disease in PReGnancy; LVOT, LV outflow tract; NYHA, New York Heart Association; SpO<sub>2</sub>, oxygen saturation as measured by pulse oximetry; ZAHARA, Zwangerschap bij Aangeboren HARTafwijkingen (pregnancy in congenital heart disease).

and withdrawal of informed consent (n=4). A total of 213 pregnancies in 203 women were observed (209 singleton and 4 twin pregnancies). None of the included women had uncorrected cyanotic disease or SpO<sub>2</sub><90%, severe pulmonary hypertension or Eisenmenger syndrome, impaired glucose tolerance or hypertensive disorder of pregnancy. Maternal baseline characteristics are shown in [table 2](#).

### Maternal cardiovascular events

The distribution of cardiovascular and offspring events by primary type of CHD are shown in [table 3](#). No maternal death occurred. Primary cardiovascular events were observed in 22 pregnancies (10.3%). Most frequent events were clinically

significant arrhythmias (n=14), followed by heart failure (n=8) and thromboembolic events (n=4). Women with a history of arrhythmia (n=19) had six cardiovascular events, including four arrhythmias. One woman underwent pacemaker implantation because of atrioventricular block. Women with a mechanical valve prosthesis (n=11) had six cardiovascular events including valvular thrombosis in four pregnancies (36.4%). Deterioration of NYHA functional class ≥2 points (secondary cardiovascular event) occurred in 39 pregnancies (18.3%).

### Offspring events

Offspring events occurred in 81 children (37.3%), corresponding to 74 pregnancies. The distribution of offspring events per

**Table 2** Maternal baseline characteristics (prior to pregnancy)

	n	(%)
<b>Demographics</b>		
Maternal age at conception (years $\pm$ SD)*	28.7	( $\pm$ 4.4)
Parity status		
0	137	(63.8)
1	58	(27.7)
$\geq 2$	18	(8.5)
<b>Clinical situation</b>		
NYHA class I	161	(75.6)
NYHA class II	51	(23.9)
NYHA class III	1	(0.5)
<b>Past medical history</b>		
Sustained symptomatic bradyarrhythmia or tachyarrhythmia requiring treatment	19	(8.9)
Left heart obstruction (PG>30 mm Hg or AVA<1.5 cm <sup>2</sup> or MVA<2 cm <sup>2</sup> )	14	(6.6)
Left heart obstruction (PG>50 mm Hg or AVA<1.0 cm <sup>2</sup> )	4	(1.9)
Systemic ventricular systolic dysfunction (EF<40%)	7	(3.3)
Cardiac medication before pregnancy†	33	(15.5)
Systemic AV valve regurgitation‡	4	(2.3)
Pulmonary AV valve regurgitation‡	12	(6.9)
Mechanical valve prosthesis	11	(5.2)
In origin cyanotic heart disease	57	(26.8)
Severe PR and/or depressed subpulmonary ventricular EF	24	(11.3)
Smoking prepregnancy	44	(21.4)
Pacemaker	8	(3.8)
Congestive heart failure	5	(2.4)
Cerebrovascular accident	3	(1.4)
Hypertension	14	6.6
<b>Medication use preconception</b>		
None	180	(84.5)
Angiotensin-converting enzyme inhibitor	2	(0.9)
Antiplatelet drugs	2	(0.9)
$\beta$ -blockers	26	(12.2)
Calcium-channel blocker	5	(2.3)
Digoxin	1	(0.5)
Diuretics	0	(0.0)
Vitamin K antagonists/Heparin	15	(7.0)

N=213 pregnancies.

\*Mean ( $\pm$ SD).

†With the exception of vitamin K antagonists/Heparin.

‡Moderate/severe.

AV, atrioventricular; AVA, aortic valve area; MVA, mitral valve area; NYHA, New York Heart Association functional class; PG, peak gradient; PR, pulmonary regurgitation.

CHD subtype is shown in table 3. Thirty children (12.2%) were born prematurely (50% due to preterm labour); 34 children (16%) were born small for gestational age; 15 children (6.9%) had respiratory distress syndrome (66.7% were born premature) and three children (1.4%) had a cerebral (intraventricular) haemorrhage. Recurrence of CHD occurred in 12 children (5.5%). Offspring death occurred in six children (2.8%). Four children died in utero (>20 weeks gestation). Two children died within 28 days after birth.

### Validation of risk scores and comparison of different risk assessment techniques

Figures 1 and 2 show the risk of primary cardiac events during pregnancy per risk assessment technique. Overestimation of cardiovascular risk (expected events>observed events) was observed in the ZAHARA I and CARPREG cardiovascular risk

scores mainly in the mid-segment and/or high-risk segment, where a relatively low number of patients could be included.

Figure 3 shows the ROC for cardiovascular events for the different risk assessment models. All ROC curves of cardiovascular events deviate significantly from the diagonal line (no discrimination), with exception of the CARPREG risk score (AUC 0.57; 95% CI 0.43 to 0.70;  $p=0.32$ ). The AUC for the ZAHARA I cardiovascular risk score was 0.71 (95% CI 0.59 to 0.83;  $p=0.001$ ). Of the five cardiovascular risk assessment models, WHO classification had the highest AUC for prediction of maternal cardiovascular events (AUC 0.77; 95% CI 0.67 to 0.87;  $p<0.0001$ ). A combination of WHO classification, TPC and DC had a slightly higher AUC: 0.80; 95% CI 0.71 to 0.90;  $p<0.0001$ ).

Figures 4 and 5 show the risk of offspring events in women with CHD per risk assessment technique. All risk assessment techniques, with the exception of DC, show an increase in offspring risk with increasing risk points, number of predictors or class. All models performed badly in predicting offspring events in our cohort, with all  $AUC\leq 0.6$ . A combination of the different risk assessment models provided the highest AUC, but still not sufficiently discriminative (AUC: 0.63).

### DISCUSSION

This study is the first to prospectively validate, compare and integrate the different risk assessment models that are used to predict cardiovascular and offspring risk during pregnancy and puerperium in women with CHD. All risk assessment models are able, to some extent, to identify women with CHD at risk of primary cardiovascular and offspring events. When comparing the five individual risk assessment models, the modified WHO classification provides the most adequate individual assessment of maternal cardiovascular risk in our cohort. For the assessment of offspring events, the difference in AUC is very small between the models. A combination of the assessment models provides the highest AUC, although not sufficiently discriminative.

### Maternal cardiovascular events

The cardiac event rate in our cohort is low compared to some other studies.<sup>5 21–23</sup> The difference in observed cardiovascular events is mainly due to differences in study population and in definition of primary and secondary cardiovascular events. Several other studies found comparable cardiovascular event rates.<sup>1 2 4 7 24 25</sup> Our cohort is a relative low-risk cohort, with 99% of women in NYHA class  $\leq$ II pre-pregnancy and no women with cyanosis or pulmonary arterial hypertension. Well organised pre-pregnancy counselling in the tertiary centres in The Netherlands prevents most high-risk women from becoming pregnant, which can explain the relatively low event rate in our cohort.

### Validation of cardiovascular risk assessment models

The ZAHARA I risk score discriminates the cardiovascular events in pregnancy better in this cohort of women with CHD than the more widely used CARPREG risk score. The AUC for ZAHARA I is higher and it deviates significantly from random guess (AUC=0.5), unlike the CARPREG risk score. The low prevalence of systemic ventricular dysfunction and high NYHA class, as well as the absence of mitral valve stenosis in our cohort is the most likely explanation. The CARPREG risk score overestimates maternal cardiovascular risk in our cohort, in line with other studies.<sup>4 5 24 25</sup>

Overall, in our cohort of women with CHD, the modified WHO classification discriminates best for cardiovascular events. This is not surprising, since the modified WHO classification



**Table 3** Distribution of cardiovascular and offspring events by primary type of congenital heart disease in 213 completed pregnancies

Maternal congenital lesion	N	%	Cardiovascular events n (%)				Offspring events n (%)	
			PCE		SCE			
Atrial septal defects	21	9.9	1	(4.8)	5	(23.8)	10	(47.6)
Ventricular septal defects	26	12.2	0	(0.0)	2	(7.7)	6	(23.1)
Atrioventricular septal defects	8	3.8	2	(25.0)	1	(12.5)	3	(37.5)
APVR	6	2.8	0	(0.0)	0	(0.0)	3	(50.0)
Pulmonary stenosis	22	10.3	1	(4.5)	1	(4.5)	9	(40.9)
AoS/BiAoV	29	13.6	4	(13.8)	9	(31.0)	13	(44.8)
Aortic coarctation	26	12.2	1	(3.8)	4	(15.4)	5	(19.2)
Connective tissue disorders*	9	4.2	1	(11.1)†	2	(22.2)	3	(33.3)
Ebstein's anomaly	4	1.9	0	(0.0)	0	(0.0)	2	(50.0)
Tetralogy of Fallot‡	40	18.8	5	(12.5)	8	(20.0)	18	(43.9)
TGA§	15	7.0	4	(26.7)	3	(20.0)	3	(20.0)
Fontan circulation	3	1.4	1	(33.3)	2	(66.7)	3	(100.0)
Other corrected complex cyanotic heart defects¶	2	0.9	1	(50.0)**	2	(100.0)	1	(50.0)
Other††	2	0.9	1	(50.0)‡‡	0	(0.0)	2	(100.0)
Total	213	100	22	(10.3)	39	(18.3)	81§§	(37.3)

Values are number of pregnancies.

\*1 Loays Dietz, all others Marfan.

†In a patient with Marfan.

‡All corrected; three patients with a double-outlet RV (Fallot type); All cardiovascular and offspring events occurred in patients with Tetralogy of Fallot.

§TGA: D-TGA with mustard or senning correction (n=12); D-TGA with arterial switch correction (n=2); congenital corrected TGA (n=1).

¶One patient with a corrected truncus arteriosus, type A; one patient with pulmonary atresia, atrial septal defect, and intact intraventricular septum.


\*\*In the patient with pulmonary atresia, atrial septal defect, and intact intraventricular septum.


††One patient with a right-sided aortic arch and one patient with an isolated cleft mitral valve, corrected with a mechanical valve (St Jude 25 mm).

‡‡In the patient with the isolated cleft mitral valve, corrected with a mechanical valve (St. Jude 25 mm).


§§81 offspring events in 213 pregnancies, including 4 twin pregnancies.

AoS/BiAoV, congenital aortic valve stenosis or bicuspid aortic valve; APVR, anomalous pulmonary venous return; PCE, primary cardiovascular events; SCE, secondary cardiovascular events; TGA, transposition of the great arteries.

**Figure 1** Expected maternal cardiovascular risk (%) and observed cardiovascular events (%) for the 'ZAHARA I' and 'CARPREG' cardiovascular risk scores.



**Figure 2** Observed maternal cardiovascular events (%) for the cardiovascular risk assessment models ‘Total number of Predictors’, ‘WHO Classification’ and ‘Disease Complexity’. CHD, congenital heart disease; DC, Disease Complexity; TP, Total number of Predictors.



**Figure 3** Receiver operating characteristic curves of maternal cardiovascular events for the different cardiovascular risk assessment models. AUC, area under the curve; ROC, receiver operating characteristic. \*Composite ROC: optimal combination of risk assessment models (WHO class, total no. cardiovascular predictors and disease complexity).


integrates all knowledge about maternal risk, including known contraindications for pregnancy which are ignored in the CARPREG and ZAHARA I risk scores, as well as known predictors found by CARPREG and other studies, underlying heart disease and other morphological and clinical variables. We recently confirmed that modified WHO class was associated with maternal complications in this population.<sup>26</sup> This is in line with recently published data from the Registry On Pregnancy And Cardiac disease (ROPAC). In this registry, modified WHO class was strongly associated with maternal cardiac events and was an independent predictor of heart failure during pregnancy.<sup>27 28</sup> A disadvantage of the WHO class may be that expert knowledge is sometimes required, especially when choosing between WHO class II and class III. Whether physicians with less expertise might make a different choice than a more experienced physician was not assessed in our study. Finally, it is important that WHO class I has a negative predictive value of 100% for maternal cardiovascular events, indicating that pregnancy is relatively safe in these women.

A combination of the risk classification systems from the WHO class with total number of cardiovascular predictors and DC provides the most adequate assessment of cardiovascular risk in pregnancy. This illustrates that integration of clinical information and predictors, or population-based information, has additional value on top of individual risk assessment models.

**Offspring events**

The offspring event rate observed in our cohort is comparable to most other studies in women with CHD.<sup>1 2 4-7 21-23 29 30</sup> Offspring death occurred in 2.8% of pregnancies. Although offspring mortality in our cohort is in accordance with previous studies in women with CHD, it is much higher than in the general Dutch population.<sup>2 4-7 23 31</sup> Also, premature births, small

**Figure 4** Expected offspring risk (%) and observed offspring events (%) for the 'ZAHARA I' risk score and observed offspring events (%) for CARPREG risk points.




for gestational age and recurrence of CHD occurred more often than would be expected in the general Dutch population. Our previous research indicated a strong association between maternal cardiac events and offspring events.<sup>2</sup> We recently found evidence that maternal cardiac function is related to uteroplacental flow parameters, while uteroplacental flow is impaired in women with CHD. Since uteroplacental flow is related to offspring outcome, the high prevalence of offspring complications in women with cardiac disease may be explained by suboptimal placental function related to maternal cardiac dysfunction.<sup>32</sup>

#### Validation of offspring risk assessment models

All risk estimation models performed insufficiently in predicting offspring risk. The risk models predicting offspring events

appear to be interchangeable, because the differences in AUC are very small, especially between ZAHARA I, CARPREG and TPO. This is explained by the huge overlap between the risk factors found by ZAHARA I and CARPREG. The ROPAC investigators reported a strong association between modified WHO class and offspring outcome, especially preterm birth and birth weight, which we could not confirm.<sup>27</sup> Our results may be explained by the fact that the modified WHO classification was not designed to assess offspring events in women with CHD, and therefore, does not take into account factors such as maternal age, parity, smoking and twin pregnancy, which are known risk factors for offspring events. This is probably also the main reason why DC alone is not an accurate predictor of offspring events.



**Figure 5** Observed offspring events (%) for 'number of offspring predictors', 'WHO risk class' and 'complexity of CHD'. CHD, congenital heart disease; DC, disease complexity.

## Key messages

### What is known on this subject?

Adequacy of prepregnancy prediction of maternal cardiovascular and offspring risk associated with pregnancy in women with congenital heart disease determines, for a large part, the efficacy of counselling prior to, and management during, pregnancy. Various studies previously validated the CARPREG risk score. The ZAHARA risk score, disease complexity, a total of all risk factors and the modified WHO classification, however, have not been validated and compared systematically before in a prospective study.

### What might this study add?

This study is the first to prospectively compare and validate the various prediction models. It shows that the modified WHO classification is the most favourable risk estimation model for cardiac risk in pregnancy, and that there are no effective risk models for the prediction of offspring events yet.

### How might this impact on clinical practice?

This study shows that the most widely used CARPREG risk score is far less accurate than the modified WHO classification. This finding will bring about a shift in use of risk score from CARPREG to the modified WHO classification.

## Strengths and limitations

The participation rate was excellent with 98% of women providing written informed consent and only two women lost to follow-up. Although inclusion rate is high, some limitations need to be addressed. Some inclusion bias might have been introduced, since only pregnancies of  $\geq 20$  weeks were taken into account. The risk estimation models that we tested may have been used in clinical practice in our study population, which may explain why no patients with a high risk of maternal death, such as Eisenmenger syndrome, could be included, and which may have improved management of pregnancies. Nevertheless, the distribution of the CHD subtypes adequately represents a tertiary hospital pregnant CHD cohort. Though women in the study mainly received standard care during their pregnancies, it cannot be excluded that their participation in the study influenced clinical management. The available risk prediction systems that we validated did not allow prediction of more threatening events such as heart failure separately from more innocent events such as supraventricular arrhythmias. The risk assessment systems that we validated have their own limitations. They do not take into account some important predictors of pregnancy outcome such as pulmonary hypertension.<sup>28</sup> NT-proBNP at 20 weeks gestation has recently been validated as a valuable parameter of pregnancy outcome but is not included in present risk scores.<sup>26</sup> Despite the limitations, our study is the first prospective study to validate, compare and integrate the available risk estimation models to predict the cardiovascular and offspring risks during pregnancy in women with CHD.

## Author affiliations

<sup>1</sup>Department of Cardiology, Isala, Zwolle, The Netherlands

<sup>2</sup>Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

<sup>3</sup>Department of Obstetrics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

<sup>4</sup>Department of Cardiology, Erasmus Medical Centre, Erasmus University, Rotterdam, The Netherlands

<sup>5</sup>Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

<sup>6</sup>Department of Cardiology, Radboud University Nijmegen Medical Centre, Radboud University Nijmegen, Nijmegen, The Netherlands

<sup>7</sup>Department of Cardiology, Medical Spectrum Twente, Enschede, The Netherlands

<sup>8</sup>Department of Cardiology, Leiden University Medical Centre, University of Leiden, Leiden, The Netherlands

<sup>9</sup>Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

**Contributors** All authors have contributed significantly to the submitted manuscript: AB, JGA, KMS-S, BJMM, JWR-H, APJvD, HWV, WD and PGP were responsible for the study design. Data collection and processing was performed by AB, TPER, AGLvdB, APJvD and EMCJW. Analysis and interpretation of the data was done by AB, HLH, PGP, JWR-H, BJMM, JGA and DJvV. The drafting of the article was performed by AB, HLH, PGP, AGLvdB, TPER, BJMM, WD and DJvV. Critical revision of the manuscript was performed by KMS-S, JWR-H, APJvD, HWV, EMCJW, WD and JGA. AB, PGP, BJMM, JWR-H and DJvV were responsible for the final approval of the version to be published.

**Funding** This work is supported by a grant from the Netherlands Heart Foundation (2007B75); DJvV is a clinically established investigator of The Netherlands Heart Foundation (D97-017).

**Competing interests** None.

**Ethics approval** The study was conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (WMO). The Medical Ethics Committee of all participating hospitals approved the study.

**Provenance and peer review** Not commissioned; externally peer reviewed.

## REFERENCES

- 1 Drenthen W, Pieper PG, Roos-Hesselink JW, *et al.* Outcome of pregnancy in women with congenital heart disease: a literature review. *J Am Coll Cardiol* 2007;49:2303–11.
- 2 Drenthen W, Boersma E, Balci A, *et al.* Predictors of pregnancy complications in women with congenital heart disease. *Eur Heart J* 2010;31:2124–32.
- 3 Fesslova VM, Villa L, Chessa M, *et al.* Prospective evaluation from single centre of pregnancy in women with congenital heart disease. *Int J Cardiol* 2009;131:257–64.
- 4 Jastrow N, Meyer P, Khairy P, *et al.* Prediction of complications in pregnant women with cardiac diseases referred to a tertiary center. *Int J Cardiol* 2010;151:209–13.
- 5 Khairy P, Ouyang DW, Fernandes SM, *et al.* Pregnancy outcomes in women with congenital heart disease. *Circulation* 2006;113:517–24.
- 6 Ouyang DW, Khairy P, Fernandes SM, *et al.* Obstetric outcomes in pregnant women with congenital heart disease. *Int J Cardiol* 2010;144:195–9.
- 7 Siu SC, Sermer M, Colman JM, *et al.* Prospective multicenter study of pregnancy outcomes in women with heart disease. *Circulation* 2001;104:515–21.
- 8 Siu SC, Colman JM, Sorensen S, *et al.* Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. *Circulation* 2002;105:2179–84.
- 9 Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. *Heart* 2006;92:1520–5.
- 10 Warnes CA, Liberthson R, Danielson GK, *et al.* Task force 1: the changing profile of congenital heart disease in adult life. *J Am Coll Cardiol* 2001;37:1170–5.
- 11 Regitz-Zagrosek V, Blomstrom LC, Borghi C, *et al.* ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). *Eur Heart J* 2011;32:3147–97.
- 12 Warnes CA, Williams RG, Bashore TM, *et al.* ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). *Circulation* 2008;118:e714–833.
- 13 Balci A, Sollie KM, Mulder BJM, *et al.* Associations between cardiovascular parameters and uteroplacental Doppler (blood) flow patterns during pregnancy in women with congenital heart disease: Rationale and design of the Zwangerschap bij Aangeboren Hartafwijking (ZAHARA) II study. *Am Heart J* 2011;161:269–75.
- 14 Vahanian A, Baumgartner H, Bax J, *et al.* A. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. *Eur Heart J* 2007;28:230–68.
- 15 Rudski LG, Lai WW, Afilalo J, *et al.* Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a



- registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr* 2010;23:685–713.
- 16 Lang RM, Bierig M, Devereux RB, *et al.* Recommendations for chamber quantification. *Eur J Echocardiogr* 2006;7:79–108.
- 17 Baumgartner H, Hung J, Bermejo J, *et al.* Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *J Am Soc Echocardiogr* 2009;22:1–23.
- 18 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982;143:29–36.
- 19 McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. *Med Decis Making* 1984;4:137–50.
- 20 Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. *Am J Epidemiol* 1982;115:92–106.
- 21 Bhatla N, Lal S, Behera G, *et al.* Cardiac disease in pregnancy. *Int J Gynaecol Obstet* 2003;82:153–9.
- 22 Ford AA, Wylie BJ, Waksmonski CA, *et al.* Maternal congenital cardiac disease: outcomes of pregnancy in a single tertiary care center. *Obstet Gynecol* 2008;112:828–33.
- 23 Song YB, Park SW, Kim JH, *et al.* Outcomes of pregnancy in women with congenital heart disease: a single center experience in Korea. *J Korean Med Sci* 2008;23:808–13.
- 24 Curtis SL, Marsden-Williams J, Sullivan C, *et al.* Current trends in the management of heart disease in pregnancy. *Int J Cardiol* 2009;133:62–9.
- 25 Stangl V, Schladt J, Gossling G, *et al.* Maternal heart disease and pregnancy outcome: a single-centre experience. *Eur J Heart Fail* 2008;10:855–60.
- 26 Kampman MA, Balci A, van Veldhuisen DJ, *et al.* N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women with congenital heart disease. *Eur Heart J* 2014;35:708–15.
- 27 Roos-Hesselink JW, Ruys TP, Stein JL, *et al.* Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. *Eur Heart J* 2013;34:657–65.
- 28 Ruys TP, Roos-Hesselink JW, Hall R, *et al.* Heart failure in pregnant women with cardiac disease: data from the ROPAC. *Heart* 2014;100:231–8.
- 29 Gelson E, Curry R, Gatzoulis MA, *et al.* Effect of maternal heart disease on fetal growth. *Obstet Gynecol* 2011;117:886–91.
- 30 Uebing A, Arvanitis P, Li W, *et al.* Effect of pregnancy on clinical status and ventricular function in women with heart disease. *Int J Cardiol* 2010;139:50–9.
- 31 Ravelli AC, Eskes M, Tromp M, *et al.* [Perinatal mortality in The Netherlands 2000–2006; risk factors and risk selection]. *Ned Tijdschr Geneesk* 2008;152:2728–33.
- 32 Pieper PG, Balci A, Aarnoudse JG, *et al.* Uteroplacental blood flow, cardiac function, and pregnancy outcome in women with congenital heart disease. *Circulation* 2013;128:2478–87.